Market Closed -
Nasdaq
02:00:01 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.9302
USD
|
+1.34%
|
|
+4.13%
|
+14.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
310.7
|
322.4
|
69.8
|
44.32
|
80.15
|
92.04
|
-
|
-
|
Enterprise Value (EV)
1 |
310.7
|
322.4
|
8.894
|
-65.66
|
80.15
|
92.04
|
92.04
|
92.04
|
P/E ratio
|
-5.07
x
|
-6.56
x
|
-1.01
x
|
-0.82
x
|
-0.94
x
|
-2.01
x
|
-1.89
x
|
-1.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
26
x
|
16.5
x
|
3.78
x
|
3.11
x
|
3.98
x
|
2.99
x
|
7.78
x
|
15.8
x
|
EV / Revenue
|
26
x
|
16.5
x
|
3.78
x
|
3.11
x
|
3.98
x
|
2.99
x
|
7.78
x
|
15.8
x
|
EV / EBITDA
|
-62,59,736
x
|
-65,61,357
x
|
-9,06,147
x
|
-6,37,217
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-71,06,010
x
|
-77,29,376
x
|
-8,88,127
x
|
-13,26,402
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.85
x
|
-
|
0.71
x
|
0.52
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,408
|
29,071
|
29,959
|
54,717
|
98,950
|
98,950
|
-
|
-
|
Reference price
2 |
12.23
|
11.09
|
2.330
|
0.8100
|
0.8100
|
0.9302
|
0.9302
|
0.9302
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11.94
|
19.58
|
18.45
|
14.25
|
20.13
|
30.79
|
11.82
|
5.833
|
EBITDA
|
-49.64
|
-49.14
|
-77.03
|
-69.55
|
-
|
-
|
-
|
-
|
EBIT
1 |
-51.08
|
-53.28
|
-81.67
|
-73.16
|
-97.69
|
-54.71
|
-108.2
|
-138
|
Operating Margin
|
-427.78%
|
-272.08%
|
-442.73%
|
-513.4%
|
-485.34%
|
-177.71%
|
-915.03%
|
-2,365.02%
|
Earnings before Tax (EBT)
1 |
-
|
-44.08
|
-75.66
|
-64.68
|
-81.21
|
-79.41
|
-109.3
|
-114.9
|
Net income
1 |
-43.04
|
-44.08
|
-75.66
|
-64.92
|
-81.58
|
-63.6
|
-85.04
|
-97.08
|
Net margin
|
-360.38%
|
-225.09%
|
-410.15%
|
-455.58%
|
-405.29%
|
-206.58%
|
-719.19%
|
-1,664.18%
|
EPS
2 |
-2.410
|
-1.690
|
-2.300
|
-0.9900
|
-0.8600
|
-0.4633
|
-0.4933
|
-0.5450
|
Free Cash Flow
|
-43.73
|
-41.71
|
-78.6
|
-33.41
|
-
|
-
|
-
|
-
|
FCF margin
|
-366.19%
|
-212.98%
|
-426.05%
|
-234.5%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
3.874
|
3.895
|
1.445
|
2.746
|
2.23
|
7.828
|
3.176
|
2.679
|
6.867
|
7.407
|
5.216
|
12.19
|
6.641
|
6.741
|
2
|
EBITDA
|
-
|
-20.82
|
-
|
-
|
-
|
-12.68
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.17
|
-22.05
|
-20.15
|
-18.43
|
-20.99
|
-13.59
|
-22.66
|
-21.47
|
-22.67
|
-30.9
|
-17.59
|
-4.214
|
-16.15
|
-16.76
|
-
|
Operating Margin
|
-546.36%
|
-566.03%
|
-1,394.26%
|
-671.05%
|
-941.39%
|
-173.58%
|
-713.38%
|
-801.49%
|
-330.13%
|
-417.11%
|
-337.31%
|
-34.57%
|
-243.2%
|
-248.57%
|
-
|
Earnings before Tax (EBT)
1 |
-20.04
|
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.08
|
-19.68
|
-18.02
|
-19.07
|
-24.65
|
-23.16
|
-8.453
|
-23.74
|
-24.06
|
-
|
Net income
1 |
-20.04
|
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.31
|
-19.68
|
-18.02
|
-19.07
|
-24.82
|
-14.43
|
-8.076
|
-16.47
|
-17.23
|
-
|
Net margin
|
-517.29%
|
-545.19%
|
-1,243.46%
|
-595.63%
|
-819.73%
|
-157.27%
|
-619.65%
|
-672.49%
|
-277.65%
|
-335.06%
|
-276.69%
|
-66.25%
|
-247.99%
|
-255.59%
|
-
|
EPS
2 |
-0.6100
|
-0.6400
|
-0.4000
|
-0.2300
|
-0.2500
|
-0.1600
|
-0.2700
|
-0.2200
|
-0.1700
|
-0.2200
|
-0.1233
|
-0.0900
|
-0.1300
|
-0.1267
|
-0.1700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
24/03/22
|
16/05/22
|
11/08/22
|
14/11/22
|
15/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
22/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
60.9
|
110
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-43.7
|
-41.7
|
-78.6
|
-33.4
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-36.5%
|
-32.2%
|
-61.6%
|
-67.6%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
143.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.600
|
-
|
3.270
|
1.560
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.340
|
-1.510
|
-2.010
|
-0.3100
|
-
|
-
|
-
|
-
|
Capex
|
2
|
2.37
|
12.6
|
5.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
16.74%
|
12.11%
|
68.2%
|
35.21%
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Last Close Price
0.9302
USD Average target price
4.6
USD Spread / Average Target +394.52% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.84% | 92.04M | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | -3.40% | 157B |
Other Pharmaceuticals
|